High-frequency (10 kHz) Spinal Cord Stimulation for the Treatment of Focal, Chronic Postsurgical Neuropathic Pain: Results from a Prospective Study in Belgium

Billet, Bart; Hanssens, Karel; Coster, Olivier De; Santos, Angela; Rotte, Anand; Minne, Veerle

doi:10.2217/pmt-2021-0045

Cited by 6 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 6 , 11 Among these SCS techniques, 10-kHz SCS was reported to decrease the mean pain score by >70% in more than 70% of patients with CPSP. 2 , 9 , 12 In our case, DTM SCS achieved 80% to 90% pain reduction of the CPSP on NRS at 3 months, which implies that DTM SCS is comparable to10-kHz SCS for the treatment of CPSP. Therefore, DTM SCS, similar to 10-kHz SCS, is expected to be a more optimal treatment option than tonic SCS, considering its efficacy, which is approximately a 50% pain reduction in the pain score of 50% of patients with other pain conditions.…”

Section: Discussionsupporting

confidence: 56%

Successful use of differential target multiplexed spinal cord stimulation for chronic postsurgical abdominal pain

Tanaka

Shinohara²,

Hidai³

et al. 2023

PR9

View full text Add to dashboard Cite

Introduction: Recent advances in stimulation techniques have improved the efficacy and expanded the applicability of spinal cord stimulation (SCS). Among these techniques, there are no reports on the efficacy of differential target multiplexed (DTM) SCS for chronic postsurgical pain (CPSP) after abdominal surgery. Therefore, we present the successful use of DTM SCS for CPSP after distal pancreatectomy. Methods: A 49-year-old man with hypertension and severe chronic low back pain presented with neuropathic CPSP involving the left abdomen in the area of a laparotomy incision. His pain was refractory to conservative treatment and was rated 10 on a numerical rating scale (NRS). He underwent permanent implantation of a pulse generator after a 14-day trial stimulation. Results: Chronic postsurgical pain was well controlled (NRS 1-2) at a 3-month follow-up with DTM SCS. Conclusion: Differential target multiplexed SCS can be a new treatment option for neuropathic CPSP that is resistant to conservative treatment. It is important to further examine the characteristics of CPSP and identify appropriate candidates for the successful use of DTM SCS.

show abstract

Section: Discussionsupporting

confidence: 56%

Successful use of differential target multiplexed spinal cord stimulation for chronic postsurgical abdominal pain

Tanaka

Shinohara²,

Hidai³

et al. 2023

PR9

View full text Add to dashboard Cite

show abstract

“…According to Xu and colleagues, for patients with refractory PDN in the lower extremities, “SCS should be considered to reduce pain and improve quality of life.” 84 D’Souza and colleagues stated that SCS should be offered to patients who have refractory PDN and fail to benefit from conservative options, such as optimization of glucose control and neuropathic analgesic medications, before strong opioids are prescribed. 2 Meanwhile, current evidence favors a shift away from traditional SCS and toward paresthesia-free HF SCS 99 as first-line neuromodulation treatment 72,100 based on an accumulation of evidence showing better outcomes for HF SCS compared with traditional SCS 101-103 for many types of pain, including PDN.…”

Section: Current Recommendations For Using Scs For Pdnmentioning

confidence: 99%

Spinal Cord Stimulation for Painful Diabetic Neuropathy

Yeung

Huang

Nguyen

et al. 2022

J Diabetes Sci Technol

View full text Add to dashboard Cite

Spinal cord stimulation (SCS) technology has been recently approved by the US Food and Drug Administration (FDA) for painful diabetic neuropathy (PDN). The treatment involves surgical implantation of electrodes and a power source that delivers electrical current to the spinal cord. This treatment decreases the perception of pain in many chronic pain conditions, such as PDN. The number of patients with PDN treated with SCS and the amount of data describing their outcomes is expected to increase given four factors: (1) the large number of patients with this diagnosis, (2) the poor results that have been obtained for pain relief with pharmacotherapy and noninvasive non-pharmacotherapy, (3) the results to date with investigational SCS technology, and (4) the recent FDA approval of systems that deliver this treatment. Whereas traditional SCS replaces pain with paresthesias, a new form of SCS, called high-frequency 10-kHz SCS, first used for pain in 2015, can relieve PDN pain without causing paresthesias, although not all patients experience pain relief by SCS. This article describes (1) an overview of SCS technology, (2) the use of SCS for diseases other than diabetes, (3) the use of SCS for PDN, (4) a comparison of high-frequency 10-kHz and traditional SCS for PDN, (5) other SCS technology for PDN, (6) deployment of SCS systems, (7) barriers to the use of SCS for PDN, (8) risks of SCS technology, (9) current recommendations for using SCS for PDN, and (10) future developments in SCS.

show abstract

“…Yet, recent advancements in technology and innovation in waveforms have yielded robust high-level clinical results, leading to the proposal for utilization of SCS earlier in the chronic pain treatment algorithm and for a broader range of painful conditions, such as painful diabetic neuropathy (PDN), chronic refractory neck pain, nonsurgical refractory back pain, in addition to FBSS and CRPS [13,14]. In particular, studies evaluating high-frequency (10 kHz) SCS for CLBP have demonstrated statistically significant and clinically meaningful improvement in pain and disability alone or when compared to conservative care [15][16][17][18][19][20][21][22].…”

Section: Introductionmentioning

confidence: 99%

Healthcare Utilization (HCU) Reduction with High-Frequency (10 kHz) Spinal Cord Stimulation (SCS) Therapy

Tieppo Francio,

Leavitt,

Alm

et al. 2024

Healthcare

View full text Add to dashboard Cite

Spinal cord stimulation (SCS) is a well-established treatment for patients with chronic pain. With increasing healthcare costs, it is important to determine the benefits of SCS in healthcare utilization (HCU). This retrospective, single-center observational study involved 160 subjects who underwent implantation of a high-frequency (10 kHz) SCS device. We focused on assessing trends in HCU by measuring opioid consumption in morphine milligram equivalents (MME), as well as monitoring emergency department (ED) and office visits for interventional pain procedures during the 12-month period preceding and following the SCS implant. Our results revealed a statistically significant reduction in HCU in all domains assessed. The mean MME was 51.05 and 26.52 pre- and post-implant, respectively. There was a 24.53 MME overall decrease and a mean of 78.2% statistically significant dose reduction (p < 0.0001). Of these, 91.5% reached a minimally clinically important difference (MCID) in opioid reduction. Similarly, we found a statistically significant (p < 0.01) decrease in ED visits, with a mean of 0.12 pre- and 0.03 post-implant, and a decrease in office visits for interventional pain procedures from a 1.39 pre- to 0.28 post-10 kHz SCS implant, representing a 1.11 statistically significant (p < 0.0001) mean reduction. Our study reports the largest cohort of real-world data published to date analyzing HCU trends with 10 kHz SCS for multiple pain etiologies. Furthermore, this is the first and only study evaluating HCU trends with 10 kHz SCS by assessing opioid use, ED visits, and outpatient visits for interventional pain procedures collectively. Preceding studies have individually investigated these outcomes, consistently yielding positive results comparable to our findings.

show abstract

High-frequency (10 kHz) Spinal Cord Stimulation for the Treatment of Focal, Chronic Postsurgical Neuropathic Pain: Results from a Prospective Study in Belgium

Cited by 6 publications

References 31 publications

Successful use of differential target multiplexed spinal cord stimulation for chronic postsurgical abdominal pain

Successful use of differential target multiplexed spinal cord stimulation for chronic postsurgical abdominal pain

Spinal Cord Stimulation for Painful Diabetic Neuropathy

Healthcare Utilization (HCU) Reduction with High-Frequency (10 kHz) Spinal Cord Stimulation (SCS) Therapy

Contact Info

Product

Resources

About